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Highlights 
Predictors of response to combination of fluoxetine and interpersonal therapy in BPD. 
Severity of BPD and specific core symptoms are predictors of response. 
Clinical response is not related to general psychopathology. 
Response is not associated with symtoms of depression and anxiety. 
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Abstract 
Objective: borderline personality disorder (BPD) is characterized by affective instability, 
impulsive behaviors, and disturbed interpersonal relationships. A previous study of our group 
found that combined therapy with interpersonal psychotherapy adapted to BPD (IPT-BPD) 
and fluoxetine was superior than single pharmacotherapy in BPD patients. The aim of the 
present study was to examine what clinical factors predicted response to combined therapy in 
patients evaluated in the previous efficacy study. 
Method: The subgroup of twenty-seven patients allocated to combined therapy was analysed. 
Patients were treated for 32 weeks with fluoxetine 20 to 40 mg/day plus IPT-BPD. Patients 
were assessed at baseline and week 32 with an interview for demographic and clinical 
variables, CGI-S, HDRS, HARS, SOFAS, BPDSI, and SAT-P. Statistical analysis was 
performed with multiple regression. The difference of CGI-S score between baseline and 
week 32 (∆ CGI-S) was the dependent variable.  
Results: Factors significantly and independently related to ∆ CGI-S were the BPDSI total 
score and the items abandonment, affective instability, and identity.  
Conclusions: Patients with more severe BPD psychopathology and with a higher degree of 
core symptoms such as fear of abandonment, affective instability, and identity disturbance 
have a better chance to improve with combined therapy with fluoxetine and IPT-BPD.  
 
Keywords: interpersonal psychotherapy, fluoxetine, combined therapy, borderline personality 
disorder, outcome, predictors. 
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1. Introduction 
Borderline personality disorder is a complex and severe mental disorder that is characterized 
by a pervasive pattern of instability of interpersonal relationships, self-image and emotions, 
and impulsive behaviors. It affects approximately 1% to 5% of the general population and as 
many as 25% of psychiatric outpatients (Gunderson and Ridolfi, 2001; Torgersen et al., 2001; 
Grant et al., 2008; Perroud et al., 2010). The long-standing impairment in functioning and 
personal distress are extensively documented in BPD. Patients affected by this disorder often 
require high treatment costs through broad use of psychiatric services (NIMHE, 2003, Ansell 
et al., 2007), stemming in part from their instability in affect and interpersonal relationships. 
In the last two decades a growing number of studies about psychotherapy of BPD have been 
performed and several treatment models have shown some evidence of efficacy, including 
mentalization-based therapy (Bateman and Fonagy, 1999; 2008), dialectical behavior therapy 
(Linehan, 1993; Linehan et al., 1999; 2006; Verheul et al., 2003), cognitive therapy 
(Davidson et al., 2006), schema-focused therapy (Kellogg and Young, 2006; Giesen-Bloo et 
al., 2006), and systems training for emotional predictability and problem solving (STEPPS) 
(Blum et al.,2002). As for transference focused therapy (Clarkin et al., 2007; Yeomans et al., 
2007), efficacy in BPD patients can be questioned as results of two controlled trials lead to 
divergent conclusions (Doering et al., 2010; Giesen-Bloo, 2006). A recent addition to these 
proposals is represented by interpersonal psychotherapy adapted to BPD (IPT-BPD), an 
intervention specifically designed for BPD patients to deal with problems in interpersonal 
contexts (Markowitz, 2005; Markowitz et al., 2006; Bellino et al., 2010). 
The standard model of IPT for major depression was modified by Markowitz and colleagues 
(2005) to address the peculiar characteristics and the complex psychopathology of patients 
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with BPD. Authors conceptualized BPD as a mood-inflected chronic illness with recurrent 
outbursts of anger requiring prolonged duration of treatment up to 34 sessions over 8 months, 
and provided a more flexible setting  to handle crises and improve compliance.   
This modified version of IPT (IPT-BPD) shows some relevant similarities with other effective 
psychotherapies, such as a clear treatment framework, attention to affect, focus on treatment 
relationship, active role of therapist, change-oriented interventions (Weinberg et al., 2011).  
Combination of a specific psychotherapy for BPD patients with drug therapy, i.e. serotonergic 
antidepressants, is common in clinical practice and was recommended as first choice for 
patients with affective dysregulation and impulsive-behavioral dyscontrol by the American 
Psychiatric Association treatment guidelines (APA, 2001, 2005). Moreover, there is some 
evidence that psychotherapy may enhance pharmacotherapy effects (WFSBP, 2007; Lieb 
2010; Stoffers 2010). 
In a randomized controlled study (Bellino et al., 2010) we compared single pharmacotherapy 
with fluoxetine 20-40 mg/day and combined therapy with IPT-BPD plus fluoxetine at the 
same dose in a sample of BPD outpatients with no psychiatric comorbidity. Results 
highlighted that combined therapy with IPT-BPD was superior than fluoxetine monotherapy 
with respect to three of the core symptoms of BPD (interpersonal relationships, affective 
instability, and impulsivity), anxiety symptoms and subjective quality of life (subjective 
perception of psychological and social functioning). According to these initial results, 
combination of antidepressants and adapted IPT can be considered as a potentially useful 
intervention in this clinical population. Nevertheless, the combined approach requires a large 
investment of clinical and economical resources and it should be targeted on selected patients. 
The need to provide clear indications for combined therapy can be addressed by investigating 
clinical predictors of response to this treatment modality.  
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The aim of the present study was to examine what demographical and clinical characteristics 
predicted response to combined therapy with IPT-BPD in the sample of BPD patients 
assessed in our previous study of efficacy (Bellino et al., 2010). Our hypothesis is that the 
association of the two treatments has more chances to induce a clinical response in patients 
with specific BPD symptoms, independently of general psychopathology and symptoms of 
anxiety and depression.  
 
2. Methods  
The present study is a further evaluation of the same BPD patients already included in our 
previous investigation (Bellino et al., 2010). The subgroup of twenty-seven patients randomly 
allocated to combined therapy with fluoxetine 20 to 40 mg/day plus IPT adapted to BPD was 
analyzed. Methods concerning trial design, selection and randomization of patients, and 
assessment instruments were the same.  
Participants were enrolled from outpatients attending the Centre for Personality Disorder of 
Psychiatric Clinic, Department of Neuroscience, University of Turin, Italy, from January to 
December 2007. Consecutive outpatients who received a DSM-IV-TR diagnosis of BPD were 
included. Exclusion criteria were: a lifetime diagnosis of delirium, dementia, amnestic 
disorder, or other cognitive disorders; schizophrenia or other psychotic disorders; bipolar 
disorder; a concomitant diagnosis of any Axis I or II disorder. Diagnoses were made by an 
expert clinician and were confirmed using the Structured Clinical Interview for DSM-IV Axis 
I or II disorders (First et al., 1997a, 1997b). Patients of childbearing age were excluded if they 
were not using an adequate method of birth control according to the judgment of the clinician. 
Patients were also excluded if receiving psychotropic drugs in the last 2 months and (or) 
psychotherapy in the last 6 months. The study was approved by the Ethical Committee of our 
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University Hospital. Written informed consent was obtained from all patients prior to their 
participation. Declaration of Helsinki guidelines were followed. 
Patients analysed in the present study were those treated with fluoxetine 20 to 40 mg per day 
associated with IPT-BPD. Psychotherapy was provided by a therapist who was not the 
psychiatrist prescribing medication and who had at least 5 years of experience practicing IPT. 
Sessions of psychotherapy were steadily supervised by a senior psychotherapist (S.B.) with 
particular attention to check for fidelity to the manual. Pharmacotherapy and psychotherapy 
were started at the same time and  lasted 32 weeks. Thirty-four sessions of IPT-BPD were 
provided. 
Patients were assessed at baseline and week 32 with the following instruments: a semi-
structured interview for clinical and demographical characteristics; the severity item of the 
Clinical Global Impression scale (CGI-S) (Guy, 1976); the Hamilton scales for depressive and 
anxious symptoms (HDRS, HARS) (Hamilton, 1959, 1960); the Social and Occupational 
Functioning Assessment Scale (SOFAS) (Goldman et al., 1992); the Satisfaction Profile 
(SAT-P) (Majani and Callegari, 1998); the Borderline Personality Disorder Severity Index 
(BPDSI) (Arntz et al., 2003).   
The CGI is a clinician-rated instrument to make global assessment of illness and consists of 
three different measures: severity of illness, global improvement, and efficacy index 
(comparison between patient’s baseline condition and a ratio of current therapeutic benefit 
and severity of side effects). In this study, we considered the first scale: severity of illness. It 
is a 7-point scale that requires the clinician to rate the severity of illness at the time of 
assessment: (1) normal, (2), borderline mentally ill, (3) mildly ill, (4) moderately ill, (5) 
markedly ill, (6) severely ill, (7) extremely ill. 
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The HDRS is a clinician-rated scale that scores severity of 21 depressive symptoms in the last 
week. Items are variably scored 0-2, 0-3, or 0-4, with a total score ranging from 0 to 64. 
Higher scores indicate more severe symptoms of depression. 
The HARS is a clinician-rated scale scoring severity of 14 symptoms of anxiety in the last 
week. Item are all scored 0-4, with a total score ranging from 0 to 56. Higher scores indicate 
more severe anxiety symptoms. 
The SOFAS is a clinician-rated scale to measure a patient’s impairment in social and 
occupational areas. It is independent of the psychiatric diagnosis and the severity of the 
patient’s symptoms. The score is ranged between 0 and 100. Higher scores indicate a better 
functioning. 
The SAT- P is a self-administered questionnaire consisting of 32 scales which provides a 
satisfaction profile in daily life and can be considered as an indicator of subjective quality of 
life. The SAT-P considers five different factors: “psychological functioning”; “physical 
functioning”; “work”; “sleep, food, and free time”; “social functioning”. The SAT-P asks the 
patient to evaluate his satisfaction in the last month for each of the 32 life aspects on a 10 
centimeter analogical scale ranging from “extremely dissatisfied” to “extremely satisfied”.  
The BPDSI is a semi-structured clinical interview assessing frequency and severity of BPD 
related symptoms. The interview consists of eight items scored on 10-point frequency scales 
(0=never; 10=daily), including ‘abandonment’, ‘interpersonal relationships’, ‘impulsivity’, 
‘parasuicidal behavior’, ‘affective instability’, ‘emptiness’, ‘outbursts of anger’, ‘dissociation 
and paranoid ideation’, and one item scored on a 4-point severity scale, concerning ‘identity’.  
Response was measured as the change of CGI-S score during the trial period. A 
comprehensive review of literature was used to identify potential predictors of response. In 
our study the putative predictors were the following: demographic characteristics (age, 
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gender, marital status), clinical features (family psychiatric history, baseline global severity of 
symptoms – CGI-S, baseline severity of depressive and anxious symptoms – HDRS, HARS, 
baseline severity of BPD symptoms – BPDSI total score and single items), and measures of 
social functioning (SOFAS) and subjective quality of life (SAT-P five factors).       
Statistical analysis was performed with analysis of variance for categorical variables (gender, 
marital status, previous hospitalization, employment), with linear regression for continuous 
variables (age, education, baseline CGI-S, HDRS, HARS, SOFAS, BPDSI total score and 
single items, SAT-P factors). Dependent variable was the difference of CGI-S score between 
baseline and week 32 (∆ CGI-S). All variables that were found significant were included in a 
multiple regression analysis (stepwise backward). Significance level was P ≤ 0.05.  
 
3. Results  
We analyzed data concerning the twenty-seven patients allocated to the arm of combined 
therapy in our previous study (Bellino et al., 2010). Five drop-outs (18.5% of the initial 
sample) were due to non-compliance. Twenty-two patients completed the trial (81.5%).  
The mean age of the sample was  26.23 ± 6.4 years; the male to female ratio was 8 to 19. 
Twelve of the 27 patients (44.4%) were married; 16 subjects (59.26%) had a previous 
hospitalization; 13 patients (48.15%) were employed.  
Table 1 reports other demographic and clinical characteristics of the participants.  
The statistical analysis of outcome measures was performed on the 22 patients who completed 
the 32 weeks of treatment. Results of ANOVA calculated for categorical variables did not 
show any significant differences of mean Δ CGI-S between groups. Continuous variables 
significantly related to Δ CGI-S at the linear regression were: SOFAS (P=0.043); BPDSI total 
score (P=0.001) and BPDSI domains abandonment (P=0,001), affective instability (P=0.030), 
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identity (P=0.001), and paranoid ideation/dissociative symptoms (P=0.008). At the multiple 
regression analysis, the following clinical variables were found significantly and 
independently related to Δ CGI-S score: BPD Severity Index total score (P=0.028) and 
BPDSI domains abandonment (P=0.001), affective instability (P=0.023), and identity 
(P=0.003). 
Table 2 and 3 display results of linear regression and multiple regression analysis. 
 
4. Discussion  
The aim of our study was to identify which demographic and clinical factors are predictors of 
response to combined treatment with the serotonergic antidepressant fluoxetine and IPT 
adapted to BPD. Our findings indicated that response to combined treatment with fluoxetine 
and IPT adapted to BPD had a positive relation with the global severity of BPD and the 
degree of a few core symptoms: fear of abandonment, affective instability and identity 
disturbance. These results are not easily comparable with those from previous investigations, 
because predictive factors of response in BPD patients were studied for some models of 
psychotherapy, but neither for IPT, nor for combined therapy with drugs. 
The first clinical implication of our findings is that clinical improvement of our patients did 
not depend on baseline severity of general symptoms, but was more specifically related to 
BPD psychopathology. This finding is basically in accordance with several studies in 
literature (Meares et al., 1999; Giesen-Bloo et al., 2006; Black et al., 2009), indicating that 
higher pre-treatment severity of BPD predicted greater symptom change with different 
models of psychotherapies (IPP-Integrative Psychotherapy Practice, Schema–focused therapy, 
Transference-focused psychotherapy,  STEPPS). Some Authors interpreted this result as “a 
meaningful indication that patients with high symptom severity actually have a great potential 
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for change and are more likely than others to experience improvement” (Black et al., 2009; 
Barnicot et al., 2012). 
With regard to specific domains of BPD symptoms, a relation with response to combined 
therapy was found for fear of abandonment.  
The intolerance to aloneness in patients affected by BPD is probably linked to the fearful 
insecure attachment style derived by precocious separation experiences (Masterson, 1976; 
Gunderson, 1996; Fossati, 2012). Patients with this clinical feature can benefit from combined 
therapy with IPT, a psychotherapy that provides a well-defined setting, a predictable duration 
and clear treatment expectations, with a good potential to accommodate their need for safety 
(Richard-Jodoin, 1989). In addition, IPT adapted to BPD included the opportunity of 
intersession contacts with therapist (one phone call/week), while combination with 
antidepressants required  the presence of a second clinician who prescribed pharmacotherapy. 
Both these characteristics of our intervention can contribute to relief abandonment feelings. 
In our analysis, another core BPD symptom predicting a better response to combined 
treatment was identity diffusion. Some Authors in efficacy-studies observed that short-term 
psychotherapy (in particular dialectical behavioral psychotherapy) can improve identity 
disturbance in patients affected by BPD enhancing the patient’s sense of self and coherence in 
their feelings and thoughts (Swann et al., 2003; Lynch et al., 2007; Rowpke et al., 2011). 
Nevertheless, in contrast with our finding, some therapy-studies showed that BPD patients 
with severe identity diffusion responded less favourably to psychotherapy than do patients 
without identity disturbance (Hull et al., 1993; Yen et al., 2009). A possible explanation for 
this discordance is that our patients were actually treated with a combination of IPT and 
drugs. We can presume that clinical improvement in patients with more refractory symptoms 
depends on the mutual reinforcement of the two treatments. BPD patients who were unable to 
12 
 
 
 
develop a stable and cohesive sense of self are burdened by a precarious e troubled worldview 
in the context of interpersonal interactions. So, a model of psychotherapy focused on 
interpersonal problems, like IPT, encourages the person to establish more balanced, realistic, 
and intimate relationships, resulting in a more coherent sense of self. 
We also found that affective dysregulation was associated with a good response to combined 
therapy. A few previous studies investigated affective instability among predictors of 
treatment outcome in BPD obtaining mixed and controversial findings (Lieb et al., 2004; 
Robins and Chapman, 2004). Bohus and colleagues (2004) and Meehan (2008) showed that 
higher level of pre-treatment affective instability, particularly expressed by outbursts of anger, 
predicted greater symptom change after treatment. On the contrary, Yen and colleagues 
(2009) in their predictor analysis did not find significant association between affective 
dysregulation at baseline and treatment outcome. According to the American Psychiatric 
Association guidelines, pharmacotherapy combined to psychotherapy has an important 
adjunctive role for diminution of affective instability (APA, 2005). 
It is interesting to notice that no demographic variables (age, gender, marital status) had 
significant effects on clinical improvement in our patients. This data confirm previous 
findings summarized  in a recent review by Barnicot et al. (2012). 
The present study suffered from some limitations. The small sample size precluded fine-
grained evaluation of various factors. Another limit was that potentially important variables 
were not evaluated: e.g. childhood trauma, therapeutic alliance, treatment process in 
psychotherapy. The exclusion of patients with Axis I and II psychiatric comorbidity implies 
that clinical characteristics of our BPD patients can be partly different from clinical practice 
and affects generalizability of our findings. On the other hand, the inclusion of BPD patients 
with concomitant psychiatric disorders could affect clinical characteristics and response to 
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treatment. So, this is a key issue in selection of patients for clinical trials.  The fourth limit 
was that assessment instruments did not include a scale designed to evaluate the specific 
mechanisms of action of IPT-BPD. In addition, as more than twenty variables were examined 
as potential predictors, type I statistical errors can occur. However, only six variables that 
were found significant at the linear regression were include in the multiple regression model. 
At last, intention-to-treat analysis was not considered neither in the efficacy trial (Bellino et 
al, 2010), nor in the present study. 
In conclusion, our study is an initial investigation aimed to identify what clinical 
characteristics of patients with BPD predicted response to a combined treatment with adapted 
IPT and fluoxetine. Patients with more severe global BPD symptoms and with higher degree 
of fear of abandonment, affective instability and disturbance of personal identity were found 
to present a better response. These results represent a preliminary confirm of our hypothesis. 
Research in this field has major clinical implications, contributing to design more specific 
treatment guidelines for homogeneous groups of BPD patients. Further investigations are 
required to replicate our results in larger samples.   
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Table 1. Baseline demographical and clinical characteristics of the sample of 27 BPD patients 
allocated to combined therapy with fluoxetine 20 to 40 mg/day and IPT-BPD. Continuous 
variables. 
Variable  Mean SD 
Age 26.23 6.4 
Education, years 12.35  4.4 
CGI-S 5.43 0.5 
HARS  12.22 2.2 
HDRS 13.12 1.9 
SOFAS 33.87 7.5 
BPDSI total score 45.14 5.6 
BPDSI interpersonal relationships 7.87 0.64 
BPDSI impulsivity 7.17 0.87 
BPDSI affective instability 7.4 1.14 
BPDSI abandonment 6.56 1.61 
BPDSI parasuicidal behavior 2.17 2.18 
BPDSI paranoid ideation  5.00 2.14 
BPDSI outburst of anger 7.2 0.756 
BPDSI emptiness 7.46 0.44 
BPDSI identity 2.48 0.92 
SAT-P psychological functioning 41.13 5.07 
SAT-P social functioning 49.97  8.81 
SAT-P physical functioning 29.69 4.2 
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SAT-P work 34.69 6.83 
SAT-P sleep, food, and free time 41.56 6.65 
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Table 2. Results of linear regression in the sample of 22 BPD patients who completed the 
combined therapy with fluoxetine 20 to 40 mg/day and IPT-BPD. The difference of CGI-S 
score between baseline and week 32 (∆ CGI-S) was the dependent variable.  Significant level 
was P ≤ 0.05. 
Variable  Coefficient SE t P 
Age - 0.207 0.062 - 1.160 0.255 
CGI-S - 0.273 0.353 - 1.553 0.131 
HARS  0.057 0.085 0.310 0.758 
HDRS 0.095 0.097 0.520 0.607 
SOFAS - 0.360 0.023 - 2.111 0.043 
BPDSI total score 0.618 0.026 4.308 0.001 
BPDSI interpersonal relationships 0.110 0.285 0.607 0.548 
BPDSI impulsivity - 0.285 0.200 - 1.630 0.114 
BPDSI affective instability 0.384 0.150 2.280 0.030 
BPDSI abandonment 0.547 0.096 3.583 0.001 
BPDSI parasuicidal behavior - 0.187 0.083 - 1.045 0.304 
BPDSI paranoid ideation  - 0.458 0.077 - 2.823 0.008 
BPDSI outburst of anger 0.008 0.244 0.046 0.963 
BPDSI emptiness - 0.203 0.413 - 1.134 0.266 
BPDSI identity 0.614 0.158 4.261 0.001 
SAT-P psychological functioning 0.198 0.036 1.104 0.279 
SAT-P social functioning 0.023 0.021 0.127 0.900 
SAT-P physical functioning 0.121 0.044 0.668 0.509 
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SAT-P work 0.066 0.027 0.360 0.721 
SAT-P sleep, food, and free time 0.262 0.027 1.488 0.147 
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Table 3. Results of multiple regression analysis (stepwise backward) in the sample of 22 BPD 
patients who completed the combined therapy with fluoxetine 20 to 40 mg/day and IPT-BPD. 
The difference of CGI-S score between baseline and week 32 (∆ CGI-S) was the dependent 
variable.  Significant level was P ≤ 0.05. 
Variable  Coefficient SE t P 
BPDSI total score 0.222 0.017 2.334 0.028 
Fear of abandonment 0.452 0.058 4.914 0.001 
Affective instability 0.242 0.089 2.422 0.023 
Identity 0.307 0.103 3.259 0.003 
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